Spiral is pleased to announce our involvement in another incredibly exciting trial, aimed at producing effective Covid-19 treatments for people in the community, not admitted to hospital.
Researchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have recently announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.
Known as PANORAMIC, this trial is led by Oxford University’s Primary Care Clinical Trials Unit, while the delivery of the trial will be supported by the NIHR Clinical Research Network and devolved administrations.
Professor Paul Little from the University of Southampton and Co-Chief Investigator has said:
‘This trial will be one of the most ambitious ever undertaken in UK primary care, and will provide vital information about treatments to help the most vulnerable people in the ongoing fight against COVID-19.’
Spiral will be supporting this trial with our savvy software platform and our ability to pivot with change. Unlike others, we can adapt our platform for Novel Trials or studies that use unusual design methodologies.
CEO and Founder of Spiral, Audrey Shearer has said:
"We have a lot of experience with platform trials including the world-renowned REMAP-CAP Trial which is seeking effective Covid-19 treatments for critical care patients. Supporting the team at Oxford University gives us the unique opportunity to help in the search for antiviral treatments that will be effective early on in the disease (PANORAMIC) and in severe cases of the disease (REMAP-CAP). Our sincere hope is that the antiviral treatments included in PANORAMIC will prevent worsening of the disease and stop people from being admitted to hospital."
PANORAMIC also has two sub-studies – the Post Exposure Prophylaxis sub-study will test whether antiviral agents prevent transmission to people living with someone who gets COVID-19; a Virology sub-study aims to find out whether the new treatments reduce viral shedding and if using the new drugs cause the virus to become resistant to treatment.
Keep up to date with the Panoramic trial via our Trial Hub page. We will be updating it as and when more information is made available.